Misys, the banking and healthcare software group, has reported better-than-expected results from Allscripts, which it bought in a controversial deal last October.

A trading update revealed a strong performance at the combined Allscripts-Misys healthcare business, where fourth-quarter order intake for traditionally licensed products was $76m (£46m) compared with $74m a year ago. Orders for its new subscription-based service rose from $8m to $27m.